Navigation Links
Essilor's 2008 First-Quarter Report
Date:4/22/2008

CHARENTON-LE-PONT, France, April 23 /PRNewswire-FirstCall/ -- Essilor International, the world leader in ophthalmic optics, today announced consolidated revenue of EUR762.2 million for the three months ended March 31, 2008, representing a reported 3.6% increase on the first quarter of 2007.

Like-for-like growth amounted to 6.2%, in line with the Company's announced annual growth target. Changes in scope of consolidation accounted for 4% of growth for the period, corresponding mainly (3.3%) to acquisitions made in 2007, with the rest contributed by businesses acquired since January 1. The 6.6% negative currency effect primarily reflected the 13.9% fall in the dollar against the euro and, to a lesser extent, the 12.6% decline in the British pound.
Consolidated revenue for the first three months of 2008

EUR millions First-quarter First-quarter % change Like-for-like

2008 change(1)

2007 as

reported

Consolidated revenue 762.2 735.6 + 3.6% + 6.2%

Europe 346.4 334.5 + 3.6% + 3.7%

North America 318.3 311.7 + 2.1% + 8.2%

Asia-Pacific 69.2 65.3 + 5.9% + 6.6%

Latin America 28.3 24.1 + 17.6% + 14.0%

(1)Based on a comparable scope of consolidation and at constant exchange rates.

In Europe, growth was impacted by the unfavorable comparison with first-quarter 2007, when revenue rose 8.6% like-for-like. In addition, there were substantially fewer selling days than in the year-earlier period. Germany and the Eastern European countries reported a strong performance.

In the United States, where demand generally remained strong, growth was led by the successful launch of the si
'/>"/>

SOURCE Essilor
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
2. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
3. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
4. VNUS Medical Technologies to Report First-Quarter 2008 Results and Webcast Teleconference on April 21
5. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
6. Abbott Hosts Conference Call for First-Quarter Earnings
7. Cardinal Health To Announce First-Quarter Results on November 5
8. NuVasive Reports First Quarter 2008 Financial Results
9. CuraGen Reports First Quarter 2008 Financial Results
10. American Cancer Society report details cancer prevention efforts
11. Albemarle Reports Record Quarterly Net Sales and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Heska Announces Extension of Credit Agreement With Wells Fargo 2Heska Announces Extension of Credit Agreement With Wells Fargo 3Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 3Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 1Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 2Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 3Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 4Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 5Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 6Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 7Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 8Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 9Golden Meditech Announces HK 24217 Million Private Equity Financing for Hospital Subsidiary 14309 1Golden Meditech Announces HK 24217 Million Private Equity Financing for Hospital Subsidiary 14309 2Method to Identify Female Athletes at a High Risk for Knee Injury Discovered 58628 1Method to Identify Female Athletes at a High Risk for Knee Injury Discovered 58628 2